Omalizumab facilitates rapid oral desensitization for peanut allergy

Peanut oral immunotherapy is a promising approach to peanut allergy, but reactions are frequent, and some patients cannot be desensitized. The anti-IgE medication omalizumab (Xolair; Genentech, South San Francisco, Calif) might allow more rapid peanut updosing and decrease reactions. We sought to ev...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of allergy and clinical immunology Vol. 139; no. 3; pp. 873 - 881.e8
Main Authors:	MacGinnitie, Andrew J., Rachid, Rima, Gragg, Hana, Little, Sara V., Lakin, Paul, Cianferoni, Antonella, Heimall, Jennifer, Makhija, Melanie, Robison, Rachel, Chinthrajah, R. Sharon, Lee, John, Lebovidge, Jennifer, Dominguez, Tina, Rooney, Courtney, Lewis, Megan Ott, Koss, Jennifer, Burke-Roberts, Elizabeth, Chin, Kimberly, Logvinenko, Tanya, Pongracic, Jacqueline A., Umetsu, Dale T., Spergel, Jonathan, Nadeau, Kari C., Schneider, Lynda C.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.03.2017 Elsevier Limited
Subjects:	Adolescent Adult Allergens - immunology Allergy and Immunology Anti-Allergic Agents - therapeutic use Arachis - immunology Arachis hypogaea Child desensitization Desensitization, Immunologic Double-Blind Method Drug dosages Female Food Food allergies food allergy Humans Immunoglobulin E - blood Immunotherapy Male omalizumab Omalizumab - therapeutic use Peanut allergy Peanut Hypersensitivity - drug therapy Peanut Hypersensitivity - therapy Peanuts Proteins Skin Tests Studies Young Adult Peanut allergy SPT ITT omalizumab EoE OIT food allergy desensitization DBPCFC Double-blind, placebo-controlled food challenge Eosinophilic esophagitis Skin prick test Oral immunotherapy Intention to treat
ISSN:	0091-6749, 1097-6825, 1097-6825
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!